 |
|
|
|
Nupen™
Nupen™ for Post-Chemotherapy Recovery of Neutrophil
Filgrastim is a human granulocyte colony-stimulating factor (“G-CSF”)‚ produced by recombinant DNA technology. NEUPOGEN® is a registered trademark of Amgen Inc. NEUPOGEN® has been shown to be safe and effective in accelerating the recovery of white blood cell counts following a variety of chemotherapy regimens and following bone marrow transplantation. We intend to use our NexACT® technology to formulate a topical formulation of Filgrastim called Nupen™ for easier administration and thus better patient compliance. In October 2010, we entered into a collaboration with the University of California San Diego (Moores Cancer Center) (“UCSD”) in which UCSD funds the bioequivalency clinical trials for Nupen™ upon the development of the optimal formulation. |
| |
|
| |
|
|
|
Pre-Clinical stage product